Breaking News

Financial Reports: Tranzyme Pharma

April 1, 2013

Revenues decline 27% in the quarter

Tranzyme Pharma

4Q Revenues: $1.6 million (-27%)

4Q Loss: $4.9 million (loss of $8.0 million 4Q11)

FY Revenues: $8.4 million (-17%)

FY Loss: $22.8 million (loss of $22.2 million FY11)

Comments: Decrease in revenue was primarily due to changes in the amortization period for revenue from the Bristol-Myers Squibb collaboration. R&D expenses were $3.5 million in the quarter compared to $7.7 million in 4Q11. The decrease was primarily due to a reduction in Phase III trial expenses for ulimorelin and our Phase IIb trial activities for TZP-102.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.